Komzifti (Ziftomenib)

Ziftomenib is a medicine for acute myeloid leukemia, a blood cancer, when the cancer has a change in a gene called NPM1 and has come back or stopped responding to treatment. It is taken as a capsule by mouth. It works by blocking a protein called menin so the leukemia cells can mature instead of multiplying.

Brand names:Komzifti
Medication

What people taking Komzifti (Ziftomenib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Komzifti (Ziftomenib) for AML (Acute Myeloid Leukemia)?

NameHow it went

About Komzifti (Ziftomenib)

What It's For

Ziftomenib, sold as Komzifti, is a prescription cancer medicine taken by mouth for adults with acute myeloid leukemia (AML). AML is a blood cancer that starts in the bone marrow, where abnormal immature white blood cells build up and crowd out the healthy cells that fight infection, carry oxygen and stop bleeding. Ziftomenib is approved only for AML that has come back after treatment (relapsed) or did not respond to it (refractory), only when the leukemia carries a change in a gene called NPM1, and only for people who have no satisfactory alternative treatment options. Because the medicine targets that specific genetic change, the leukemia is tested for an NPM1 mutation before ziftomenib is considered. It is not approved for children or for AML driven by a different genetic change called a KMT2A rearrangement. Using it together with other leukemia drugs, or for newly diagnosed AML, is being studied in clinical trials but is not an approved use. Another medicine of the same type, revumenib (Revuforj), is approved for relapsed or refractory NPM1-mutated AML in adults and in children 1 year and older.

How It Works

In this form of leukemia, the mutated NPM1 protein collects in the wrong part of the cell. From there it helps keep a set of cancer-promoting genes switched on, which holds blood-forming cells in an immature state where they keep multiplying instead of developing into normal blood cells. That switching depends on two proteins working together, menin and KMT2A. Ziftomenib is a menin inhibitor: it blocks menin from binding KMT2A. With that partnership broken, the mutant NPM1 loses its ability to drive the leukemia, and the leukemia cells begin to mature (differentiate). The same maturing effect is behind the medicine's most important risk, differentiation syndrome, described under Side Effects.

Dosage & Administration

Ziftomenib comes as 200 mg capsules. The usual dose is 600 mg (three capsules) taken once a day, at about the same time each day, on an empty stomach: at least 1 hour before or 2 hours after a meal. The capsules are swallowed whole and should not be opened, broken or chewed. If the white blood cell count is high, another medicine is usually given first to bring it down before ziftomenib starts, as a precaution against differentiation syndrome (described under Side Effects). If side effects become severe, the care team may pause the medicine or lower the dose; dose changes should only be made with them. If a dose is missed, take it as soon as possible the same day, as long as it is at least 12 hours before the next scheduled dose, then return to the usual schedule the next day. Never take two doses within 12 hours of each other.

Side Effects

The most serious risk is differentiation syndrome, the subject of the medicine's boxed warning (the most prominent safety warning the US Food and Drug Administration requires). It happens when large numbers of leukemia cells mature at once, and it can affect breathing, blood pressure, the kidneys and fluid balance. In the main study it affected about 1 in 4 people and was fatal in 2 of 112. It usually began within the first few weeks, most often about two weeks in, but it can occur at other times during treatment. Warning signs of differentiation syndrome include fever, shortness of breath or trouble breathing, cough, chest pain, dizziness, joint or bone pain, rash, rapid weight gain, swelling of the hands, feet, ankles or legs, and passing less urine. If any of these appear, contact the care team right away or go to the nearest emergency room, and say that you take ziftomenib. When it is recognized, the usual response is to pause ziftomenib, give a corticosteroid such as dexamethasone and monitor closely until symptoms settle, then restart. Other common side effects include infections, bleeding or easy bruising, fever with a low white blood cell count (febrile neutropenia), diarrhea, nausea, tiredness, swelling in the arms and legs, muscle, bone and joint pain, itching and changes in liver blood tests. Serious side effects were frequent in the study (79% of people had at least one), most often infections, and about 1 in 5 people stopped the medicine because of a side effect.

Interactions & Warnings

Ziftomenib can cause QT prolongation, a change in the heart's electrical activity seen on an electrocardiogram (ECG) that can lead to a dangerous irregular heartbeat. The care team checks an ECG and blood levels of potassium and magnesium before starting, repeats the ECG at least weekly for the first four weeks and at least monthly after that, and does not usually start treatment if the ECG already shows a long QT interval. People with long QT syndrome, heart failure, or low potassium or magnesium may need more frequent checks. Feeling faint, lightheaded or dizzy, or a heartbeat that feels fast or irregular, should be reported to the care team right away. Fainting or passing out needs emergency care. Several kinds of medicines change how ziftomenib works. Other medicines that also prolong the QT interval are avoided when possible, or require extra ECGs. Medicines that reduce stomach acid lower how much ziftomenib the body absorbs, and many are sold over the counter for heartburn. Proton pump inhibitors (PPIs), such as omeprazole (Prilosec), should be avoided. H2 blockers, such as famotidine (Pepcid), and antacids, such as calcium carbonate (Tums), are also best avoided. If an H2 blocker is needed, ziftomenib is taken 2 hours before or 10 hours after it. If an antacid is needed, ziftomenib is taken 2 hours before or 2 hours after it. Some medicines speed up the liver's breakdown of ziftomenib and can make it less effective, so they are avoided; examples are rifampin (an antibiotic used for tuberculosis) and the herbal supplement St. John's wort. Others slow that breakdown and raise ziftomenib levels, which calls for closer watching for side effects; these include certain antifungal medicines, such as posaconazole and voriconazole, that are often used to prevent infections during leukemia treatment. Because of this, the care team and pharmacist should review every prescription, over-the-counter medicine, vitamin and herbal supplement, including new ones from other doctors. Ziftomenib can harm a developing baby. Women who could become pregnant have a pregnancy test before starting, use effective birth control during treatment and for 6 months after the last dose, and should tell the care team about a known or suspected pregnancy. Men with partners who could become pregnant use effective birth control during treatment and for 3 months after. Breastfeeding is not recommended during treatment and for 2 weeks after the last dose. Animal studies suggest the medicine may also affect fertility in both men and women, which is worth raising before starting.

What to Expect

The first weeks of treatment involve close follow-up: frequent blood counts, ECGs and watching for differentiation syndrome. Benefit is not immediate. Among people who responded in the main study, the typical time to remission was nearly 3 months, and almost 9 in 10 of those who responded did so within 6 months. For that reason, ziftomenib is usually continued for at least 6 months unless the leukemia clearly worsens or side effects cannot be managed, and after that for as long as it keeps working and is tolerated. Results should be weighed realistically. In the study of 112 adults (median age 69) whose NPM1-mutated AML had relapsed or stopped responding, about 1 in 5 reached a complete remission, meaning the bone marrow no longer showed signs of active leukemia, with blood counts fully or partly recovered. Those remissions lasted a median of about 5 months. About 1 in 5 people who had needed regular red blood cell or platelet transfusions went at least two months without them. The study had no comparison group, so it does not show how ziftomenib compares with other options or whether it helps people live longer. A few people (4 of 112) went on to a stem cell transplant.

Questions to Ask Your Doctor

  1. 1.How was my leukemia tested for an NPM1 mutation, and why is ziftomenib a better fit for me than revumenib, a clinical trial or another treatment?
  2. 2.Which signs of differentiation syndrome should I watch for, and who should I call day or night if they appear?
  3. 3.How often will I need blood tests and ECGs, and do any of my current medicines, including stomach acid reducers, need to change?
  4. 4.How will we know whether ziftomenib is working, and what is the plan if there is no response after 6 months?
  5. 5.Could a remission make a stem cell transplant possible for me, and what would that involve?

Last reviewed • Oct 2026

Educational content, not medical advice.